|
Clinical relevance of St. John's wort drug interactions revisited.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) |
|
ID |
4523061 |
Author(s) |
Nicolussi, Simon; Drewe, Jürgen; Butterweck, Veronika; Meyer zu Schwabedissen, Henriette E |
Author(s) at UniBasel |
Meyer zu Schwabedissen, Henriette
|
Year |
2020 |
Title |
Clinical relevance of St. John's wort drug interactions revisited. |
Journal |
British journal of pharmacology |
Volume |
177(6) |
Pages / Article-Number |
1212-1226 |
Keywords |
Cytochrome P450; Hypericum perforatum; drug-drug interactions; herb-drug interaction; hyperforin |
Abstract |
The first clinically relevant reports of St. John's wort (SJW) interacting with drugs, altering their bioavailability and efficacy, were published around millennium: In 2000, a pharmacokinetic interaction between SJW and cyclosporine caused acute rejection in two heart transplant patients. Since then, subsequent research has shown that SJW altered the pharmacokinetics of several drugs such as digoxin, tacrolimus, indinavir, warfarin, alprazolam, simvastatin, or oral contraceptives. Research revealed that these interactions were caused by pregnane-X-receptor (PXR) activation. SJW is a potent activator of PXR and hence inducer of cytochrome P450 enzymes (most importantly CYP3A4) and P-glycoprotein. The degree of CYP3A4 induction correlates significantly with the hyperforin content in the product. Twenty years after the first occurrence of clinically relevant pharmacokinetic drug interactions with SJW, this review revisits the current knowledge on the mechanisms of action and on how pharmacokinetic drug interactions with SJW could be avoided. |
ISSN/ISBN |
1476-5381 |
Full Text on edoc |
|
Digital Object Identifier DOI |
10.1111/bph.14936. |
PubMed ID |
http://www.ncbi.nlm.nih.gov/pubmed/31742659 |
|
|
|
MCSS v5.8 PRO. 0.519 sec, queries - 0.000 sec
©Universität Basel | Impressum
| |
29/03/2024
Research Database / FORSCHUNGSDATENBANK
|